MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.56 USD
+0.11 (3.19%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $3.56 0.00 (0.00%) 6:54 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for MacroGenics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 230 | 154 | 244 | 273 | 216 |
Receivables | 10 | 56 | 10 | 23 | 13 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 4 | 0 | 0 |
Other Current Assets | 10 | 10 | 21 | 17 | 11 |
Total Current Assets | 251 | 222 | 280 | 313 | 240 |
Net Property & Equipment | 22 | 30 | 38 | 42 | 48 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 18 | 24 | 25 |
Total Assets | 298 | 280 | 335 | 379 | 313 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 16 | 8 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 29 | 34 | 34 | 27 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 22 | 10 | 21 | 4 | 11 |
Total Current Liabilities | 56 | 49 | 75 | 51 | 45 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 59 | 59 | 0 | 7 | 9 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 146 | 138 | 96 | 83 | 82 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 1,255 | 1,235 | 1,213 | 1,067 | 872 |
Retained Earnings | -1,103 | -1,094 | -974 | -772 | -642 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 153 | 142 | 240 | 296 | 231 |
Total Liabilities & Shareholder's Equity | 298 | 280 | 335 | 379 | 313 |
Total Common Equity | 153 | 142 | 240 | 296 | 231 |
Shares Outstanding | 62.00 | 61.40 | 61.20 | 56.20 | 48.90 |
Book Value Per Share | 2.46 | 2.31 | 3.92 | 5.26 | 4.72 |
Fiscal Year End for MacroGenics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 140 | 184 | 230 | 256 | 240 |
Receivables | 6 | 7 | 10 | 25 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 1 |
Other Current Assets | 9 | 10 | 10 | 9 | 6 |
Total Current Assets | 157 | 203 | 251 | 291 | 255 |
Net Property & Equipment | 20 | 21 | 22 | 23 | 24 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 201 | 248 | 298 | 340 | 306 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 11 | 6 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 18 | 24 | 25 | 28 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 24 | 23 | 22 | 19 | 10 |
Total Current Liabilities | 58 | 56 | 56 | 51 | 45 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 56 | 56 | 59 | 64 | 59 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 143 | 142 | 146 | 146 | 134 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,268 | 1,261 | 1,255 | 1,250 | 1,245 |
Retained Earnings | -1,211 | -1,155 | -1,103 | -1,057 | -1,074 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 58 | 106 | 153 | 194 | 172 |
Total Liabilities & Shareholder's Equity | 201 | 248 | 298 | 340 | 306 |
Total Common Equity | 58 | 106 | 153 | 194 | 172 |
Shares Outstanding | 62.60 | 62.50 | 62.00 | 61.90 | 61.80 |
Book Value Per Share | 0.92 | 1.70 | 2.46 | 3.13 | 2.78 |